Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 338972
                    [Title] => Hepatitis B treatment strategies
                    [Summary] => Hepatitis B  virus (HBV) is a transmissible, fibrogenic and oncogenic virus for which there are a continually expanding number of well-tolerated treatment options. The decision to treat patients with chronic hepatitis B (CHB) should be based  on rapidly emerging data and knowledge of the clinical consensus regarding CHB. There is no way to predict reliably which patients will experience the sequelae of CHB – complications of cirrhosis and hepatocellular carcinoma (HCC) – or time-to-onset of these clinical endpoints.
                    [DatePublished] => 2006-05-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 274759
                    [Title] => New hepa B treatment cited
                    [Summary] => At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited. 


Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.


The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B. 


                    [DatePublished] => 2005-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

HBEAG

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 338972
                    [Title] => Hepatitis B treatment strategies
                    [Summary] => Hepatitis B  virus (HBV) is a transmissible, fibrogenic and oncogenic virus for which there are a continually expanding number of well-tolerated treatment options. The decision to treat patients with chronic hepatitis B (CHB) should be based  on rapidly emerging data and knowledge of the clinical consensus regarding CHB. There is no way to predict reliably which patients will experience the sequelae of CHB – complications of cirrhosis and hepatocellular carcinoma (HCC) – or time-to-onset of these clinical endpoints.
                    [DatePublished] => 2006-05-28 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 274759
                    [Title] => New hepa B treatment cited
                    [Summary] => At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited. 


Peginterferon alfa 2-a has been shown to treat both HbeAG-positive and HbeAG-negative chronic hepatitis B, thus removing the need for daily and potentially life-long therapy for the disease.


The studies presented during the conference showed that peginterferon alfa 2-a is superior to lamivudine, the most commonly prescribed medication for hepatitis B. 


                    [DatePublished] => 2005-04-21 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Hepatitis B treatment strategies

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | May 28, 2006 - 12:00am

Hepatitis B virus (HBV) is a transmissible, fibrogenic and oncogenic virus for which there are a continually expanding number of well-tolerated treatment options. The decision to treat patients with chronic hepatitis...

Opinion

New hepa B treatment cited

April 21, 2005 - 12:00am

At the recent 14th biennial conference of the Asian Pacific Association for the Study of the Liver, a new hepatitis B treatment option was cited. Peginterferon alfa 2-a has been shown to treat both HbeAG-positive...

Science and Environment